ArticleNature reviews. Neurology2011
Neurodegenerative disease: Pridopidine for Huntington disease falls short of primary efficacy end point in phase III trial.
No numbers read from the abstract.
ArticleNature reviews. Neurology2011
No numbers read from the abstract.